Tocilizumab after A First-Line with Anti-Tnf in Rheumatoid Arthritis- A Cost-Consequence Analysis in the Italian Setting
Oct 1, 2017, 00:00 AM
10.1016/j.jval.2017.08.762
https://www.valueinhealthjournal.com/article/S1098-3015(17)31096-3/fulltext
Section Title :
Disease-Specific Studies
Section Order :
727
First Page :
A533
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31096-3&doi=10.1016/j.jval.2017.08.762